Table 2. Comparisons of patients’ characteristics and other variables between MW ablation group and RF ablation group in the entire cohort.
| Variables | Before PSM* | After PSM | ||||
|---|---|---|---|---|---|---|
| MW Group | RF Group | P value | MW Group | RF Group | P value | |
| PS score | 0.29 (0.22) | 0.43 (0.21) | 0.000 | 0.46 (0.21) | 0.48 (0.21) | 0.641 |
| Sex | ||||||
| male | 173 (79.4%) | 192 (82.1%) | 0.468 | 92 (80.0%) | 88 (76.5%) | 0.525 |
| female | 45 (20.6%) | 42 (17.9%) | 23 (20.0%) | 27 (23.5%) | ||
| Age | 56.4±10.3 | 57.3±9.3 | 0.323 | 56.3±10.0 | 57.5±9.4 | 0.315 |
| ≤60 | 137 (62.8%) | 143 (61.1%) | 0.705 | 74 (64.3%) | 69 (60.0%) | 0.499 |
| >60 | 81 (37.2%) | 91 (38.9%) | 41 (35.7%) | 46 (40.0%) | ||
| ASA score* | ||||||
| Ⅱ | 169 (77.5%) | 195 (83.3%) | 0.119 | 88 (76.5%) | 87 (75.7%) | 0.878 |
| Ⅲ | 49 (22.5%) | 39 (16.7%) | 27 (23.5%) | 28 (24.3%) | ||
| Hypertension (Yes/No) | 41/177 | 68/166 | 0.011 | 26/89 | 37/78 | 0.105 |
| Diabetes (Yes/No) | 31/187 | 31/203 | 0.198 | 17/98 | 19/96 | 0.718 |
| Cardiopathy** (Yes/No) | 5/213 | 14/220 | 0.051 | 2/113 | 7/108 | 0.171 |
| Tumor number | ||||||
| 1 | 177 (81.2%) | 202 (86.3%) | 0.333 | 96 (83.5%) | 95 (82.6%) | 0.983 |
| 2 | 37 (17.0%) | 29 (12.4%) | 17 (14.8%) | 18 (15.7%) | ||
| 3 | 4 (1.8%) | 3 (1.3%) | 2 (1.7%) | 2 (1.7) | ||
| Cirrhosis (Yes/No) | 176/42 | 185/49 | 0.657 | 85/30 | 87/28 | 0.763 |
| HBV/HCV* infection (Yes/No) | 190/28 | 213/32 | 0.945 | 98/17 | 97/18 | 0.855 |
| Adjuvant chemoradiotherapy*** | ||||||
| (Yes/No) | 28/190 | 90/144 | 0.000 | 19/96 | 26/89 | 0.247 |
| Child-Pugh stage | ||||||
| A | 200 (91.7%) | 216 (92.3%) | 0.825 | 107 (93.0%) | 105 (91.3%) | 0.625 |
| B | 18 (8.3%) | 18 (7.7%) | 8 (7.0%) | 10 (8.7%) | ||
| Tumor size | 2.9±1.2 | 2.4±1.0 | 0.000 | 2.4±1.1 | 2.6±1.1 | 0.465 |
| <3cm | 110 (50.5%) | 166 (70.9%) | 0.000 | 80 (69.6%) | 74 (64.3%) | 0.400 |
| ≥3cm | 108 (49.5%) | 68 (29.1%) | 35 (30.4%) | 41 (35.7%) | ||
| Anesthetic methods | ||||||
| General anesthesia | 56 (25.7%) | 155 (66.2%) | 0.000 | 31 (27.0%) | 40 (34.8%) | 0.201 |
| Local anesthesia | 162 (74.3%) | 79 (33.8%) | 84 (73.0%) | 75 (65.2%) | ||
| AFP* | ||||||
| <400ng/ml | 179 (82.1%) | 201 (85.9%) | 0.272 | 101 (87.8%) | 98 (85.2%) | 0.564 |
| ≥400ng/ml | 39 (17.9%) | 33 (14.1%) | 14 (12.2%) | 17 (14.8%) | ||
| TBIL* | ||||||
| <34mmol/L | 201 (92.2%) | 211 (90.2%) | 0.447 | 106 (92.2%) | 103 (89.6%) | 0.494 |
| ≥34mmol/L | 17 (7.8%) | 23 (9.8%) | 9 (7.8%) | 12 (10.4%) | ||
| ALB* | ||||||
| ≤35g/L | 32 (14.7%) | 36 (15.4%) | 0.834 | 11 (9.6%) | 14 (12.2%) | 0.527 |
| >35g/L | 186 (85.3%) | 198 (84.6%) | 104 (90.4%) | 101 (87.8%) | ||
| ALT* | ||||||
| <40U/L | 128 (58.7%) | 144 (61.5%) | 0.540 | 72 (62.6%) | 63 (54.8%) | 0.230 |
| ≥40U/L | 90 (41.3%) | 90 (38.5%) | 43 (37.4%) | 52 (45.2%) | ||
| AST* | ||||||
| <40U/L | 134 (61.5%) | 133 (56.8%) | 0.317 | 75 (65.2%) | 65 (50.4%) | 0.177 |
| ≥40U/L | 84 (38.5%) | 101 (43.2%) | 40 (34.8%) | 50 (49.6%) | ||
| Inpatient days# | ||||||
| ≤5 days | 213 (97.7%) | 222 (94.9%) | 0.113 | 113 (98.3%) | 107 (93.0%) | 0.102 |
| >5 days | 5 (2.3%) | 12 (5.1%) | 2 (1.7%) | 8 (7.0%) | ||
*ASA, American Society of Anesthesiologists; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; TBIL, total bilirubin; ALB, serum albumin; ALT, Alanine transaminase; AST, aspartate aminotransferase; PSM, propensity score matching.
** Cardiopathy illnesses include coronary heart disease, heart failure (NYHA Ⅰ-Ⅱ), arrhythmia, myocardiopathy and valvulopathy.
*** Adjuvant chemoradiotherapy includes transcatheter arterial chemoembolization (TACE) and radioactive seed implantation. Adjuvant chemoradiotherapy is defined as patients received TACE or radioactive seed implantation during the hospital admission for first treatment.
#Inpatient days is defined as the period from operation finished to hospital discharge.